Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Durham, North Carolina 27710


Hypothesis: In selected patients external hyperthermia will be used in combination with intravesical Mitomycin-C to treat recurrent TCC of the bladder after local resection and standard adjuvant therapy and thus prevent or delay recurrence and the need for radical cystectomy.


Inclusion Criteria: - Non-muscle invasive TCC of the bladder (Ta, T1, Tis) recurrent after initial surgery and at least one round of adjuvant treatment (i.e. 6 weeks of intravesical biological therapy with BCG solution); or - An inability to tolerate BCG - Age > 18 - ECOG Performance Status 0-2 - Laboratory tests performed within 14 days of study enrollment: - Leukocytes ≥ 3,200, Absolute Neutrophil count ≥ 1,500, Platelets ≥ 100,000 - Hemoglobin ≥ 9.0 gm/dL, Total bilirubin ≤ institution upper limit of normal *(ULN), AST and ALT ≤ 2.5 times ULN, Alkaline phosphatase ≤ 2.5 times ULN - Creatinine ≤ 1.5 times ULN - Women of child bearing potential must have a negative pregnancy test - If post-menopausal - Amenorrhea for ≥ 12 months Exclusion Criteria: - Pregnancy or breastfeeding - Muscle invasive disease (T2-T4) - Prior radiation to the pelvis - Peripheral neuropathy (any grade) - Thrombocytopenia, coagulation disorder or an increase in bleeding tendency due to other causes - Known bladder fistula - Hypersensitive or idiosyncratic reaction to mitomycin-C or its components in the past

Study is Available At:

Original ID:




Secondary ID:

Study Acronym:

Brief Title:

Mitomycin C With Hyperthermia for Non-muscle Invasive Bladder Cancer

Official Title:

Pilot Study of External Hyperthermia and Intravesical Mitomycin-C To Treat Recurrent Bladder Cancer After Resection and Standard Adjuvant Therapy

Overall Status:

Active, not recruiting

Study Phase:




Minimum Age:

18 Years

Maximum Age:

75 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Duke University

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Non-Randomized, Endpoint Classificati

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Zeljko Vujaskovic, MD, PhD
Principal Investigator
Duke University

Study Dates

Start Date:April 2008
Completion Date:September 2011
Completion Type:Anticipated
Primary Completion Date:February 2011
Primary Completion Type:Anticipated
Verification Date:October 2010
Last Changed Date:October 13, 2010
First Received Date:May 4, 2008

Study Outcomes

Outcome Type:Primary Outcome
Measure:To assess the safety and tolerability of administering local bladder hyperthermia and intravesical mitomycin-C, as second-line treatment of recurrent TCC of the bladder after failing initial surgery and standard adjuvant therapy.
Time Frame:1 year
Safety Issues:True
Outcome Type:Secondary Outcome
Measure:To estimate the time to second recurrence using this thermo intravesical chemotherapy treatment regimen.
Time Frame:1 year
Safety Issues:False

Study Interventions

Intervention Type:Device
Name:BSD 2000 Hyperthermia System
Description:Mitomycin C 40 mg solution instilled into bladder Hyperthermia applied to heat the bladder to a temperature of 42 degrees Celsius for 40-60 minutes concurrent with mitomycin Treatment Schedule: 6 Weekly Sessions (Induction) followed by 4 Monthly Sessions (Maintenance) until documented second recurrence
Arm Name:1

Study Arms

Study Arm Type:Experimental
Arm Name:1
Description:Mitomycin C and Hyperthermia

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:Duke University

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.